The 26% discount to the prior close signals aggressive capital needs for a pre-revenue clinical-stage biotech. Monitor the stock for continued selling pressure as the offering settles on July 28. The shareholder meeting on September 11, 2026, for warrant approval and the Australian Placement components introduces overhang. Watch for any clinical data updates on RAD101 or RAD204 that could offset dilution concerns.
Price Chart
Executive Summary
Radiopharm Theranostics is raising approximately $4.05M in gross proceeds through a registered direct offering of 1,281,646 ADSs at $3.16 per ADS, a ~26% discount to the last closing price of $4.29. The offering includes concurrent unregistered warrants exercisable at $3.79 per ADS. Combined with an Australian Placement raising A$6.7M and a Share Purchase Plan for up to A$6M, the company is pursuing a multi-tranche capital raise totaling roughly $10M+ USD. The proceeds are earmarked for clinical development programs including a registrational Phase 3 study for RAD101. The dilutive impact is significant given the company's ~$45M market cap, and the 26% discount signals urgency in capital needs for a pre-revenue biotech.
Key Facts
- Radiopharm is offering 1,281,646 ADSs at $3.16 per ADS, a ~26% discount to the July 21 closing price of $4.29.
- Gross proceeds of ~$4.05M from the ADS offering; net proceeds estimated at ~$3.3M after fees and expenses.
- Concurrent private placement of warrants to purchase up to 1,281,646 ADSs at $3.79 per ADS, exercisable after shareholder approval, expiring July 31, 2029.
- Separate Australian Placement raising A$6.7M (~$4.5M USD) from institutional investors, plus a Share Purchase Plan for up to A$6M (~$4M USD).
- Pro forma net tangible book value per ADS increases from $0.61 to $0.77, but the offering price of $3.16 represents a 310% premium to book value.
- Proceeds intended for RAD101 registrational Phase 3 study preparation, RAD 204 dose escalation, and other pipeline programs.
- H.C. Wainwright is acting as exclusive placement agent, receiving 7.0% cash fee plus warrants for 64,082 ADSs at $3.95 per ADS.
- 30-day lock-up on further ADS issuances and 12-month restriction on variable rate transactions.
Financial Impact
Dilutive equity offering raising ~$4.05M gross at a 26% discount to market, with additional A$12.7M from Australian placements and share purchase plan. Total potential dilution from ADS offering alone is ~10% of pre-offering shares outstanding (based on 3.54B ordinary shares pre-offering vs 384.5M new ordinary shares).
Risk Factors
- Significant dilution to existing shareholders from the ADS offering and concurrent Australian placements.
- 26% discount to market price suggests distressed capital raising conditions and potential further downside.
- Warrant overhang: up to 1.28M additional ADSs exercisable at $3.79, representing potential future dilution.
- Pre-revenue biotech with no approved products; clinical trial execution risk for RAD101 Phase 3 and other pipeline programs.
- Shareholder approval required for portions of the Australian Placement and warrants, creating execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-081556 |
| Document: 0001213900-26-081556-index-headers.html | 0001213900-26-081556 |
| Document: 0001213900-26-081556-index.html | 0001213900-26-081556 |
| Document: 0001213900-26-081556.txt | 0001213900-26-081556 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $0.9485 | awaiting T+5 | — | $0.9960 (+5.01%) |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9960 (+0.61%) |
Oct 14, 2026 12d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9960 (−7.78%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9960 (−21.57%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9960 (−32.70%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9960 (−38.52%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9960 (+36.64%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9960 (−39.64%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9960 (−50.45%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9960 (−49.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers